Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

IELSG32 study investigators

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1870-1878
Number of pages9
JournalLeukemia
Volume36
Issue number7
DOIs
Publication statusE-pub ahead of print - Jul 2022

Cite this